Abstract
Rationale Circulating fibrocytes are elevated in idiopathic pulmonary fibrosis, but the relationship between fibrocyte level with lung function decline and clinical outcomes remains controversial.
Objective To provide evidence for the utility of circulating fibrocyte levels as a prognostic biomarker in pulmonary fibrosis.
Methods We tested associations between circulating fibrocyte levels, mortality, disease progression and longitudinal lung function in a well-defined prospective observational study of pulmonary fibrosis (PROFILE; NCT01134822). A subset of recruited participants had blood samples processed for fibrocyte measurement, with flow cytometry based on CD45 and collagen-I gating. Associations were tested using univariate and multivariate generalised linear models. Mortality data were combined with an independent study in a weighted-pooled analysis.
Measurements and Main Results In 119 participants with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia, circulating fibrocytes were elevated but not significantly above healthy controls. In multivariate analyses, each increment in circulating fibrocyte was associated with a 4% increased risk of overall mortality (Hazard Ratio 1.04 95% CI 1.00–1.09). A weighted-pooled analysis of idiopathic pulmonary fibrosis alone supported these observations in a larger sample of 162 participants, a 5% rise in fibrocytes was associated with a 24% increase in adjusted mortality risk (Hazard Ratio 1.24 95% CI 1.06–1.46). We found no association of fibrocytes with lung function or disease progression.
Conclusions In a large prospective clinical cohort of pulmonary fibrosis, circulating fibrocytes can be isolated and increased levels are associated with increased mortality but do not associate with disease related decline in lung function.
Competing Interest Statement
TMM has, via his institution, received industry-academic funding from GlaxoSmithKline and UCB as well as consultancy or speakers fees from AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, GlaxoSmithKline, ProMetic, Roche, Sanumed and UCB as well as stock options from Apellis, outside the submitted work. TMM has received industry-academic funding from GlaxoSmithKline (GSK) R&D, UCB, and Novartis and has received consultancy or speakers fees from AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, GSK R&D, Lanthio, InterMune, ProMetic, Roche, Sanofi-Aventis, Takeda, and UCB. RGJ reports grants from GlaxoSmithKline, the UK Medical Research Council, Biogen, Galecto and MedImmune as well as personal fees from Boehringer Ingelheim, GlaxoSmithKline, InterMune, MedImmune, PharmAkea, Roche and Pulmatrix, outside the submitted work; he has served as a consultant for Pliant Therapeutics and MuMedii and a trustee for the charities Action for Pulmonary Fibrosis and the British Thoracic Society. RGJ has received industry-academic funding from Galecto, GSK R&D, MedImmune, Novartis, and Biogen and has received consultancy or speakers fees from Biogen, Boehringer Ingelheim, GSK R&D, InterMune, MedImmune, PharmAkea, Pulmatrix, and Roche.
Clinical Trial
NCT01134822
Funding Statement
This work was funded by grants from GSK, UK MRC and NIHR grants.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval from University ethics committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available from the Study Steering Committee at reasonable request